Skip to content
CLADsolve

Paper

Humoral immunity to lung antigens early post-transplant confers risk for chronic lung allograft dysfunction.

Evidence level: retrospective single-centre cohort (89 recipients); abstract-only

A single-centre Toronto study of 89 bilateral lung transplant recipients reporting that certain autoantibodies at 6 months after transplant, and de novo donor-specific antibodies, were associated with CLAD.

As of . Primary source: Publisher record via DOI.

Summary

According to the abstract, serum from 89 crossmatch-negative bilateral recipients was screened at the time of transplant and 6 months later with a custom antigen microarray, before any CLAD diagnosis, and related to de novo donor-specific antibody (dnDSA) exposure and CLAD-free survival. Patients who developed CLAD by 5 years showed a decrease in average IgG reactivity at 6 months. IgG antibodies against tropoelastin, surfactant protein D and thyroglobulin were significantly higher at 6 months in patients who developed CLAD by 5 years, whereas IgG anti-CENP-B (at both time points) and PM/SCL100 (at 6 months) were higher in patients who remained CLAD-free. The abstract states that exposure to autoantibodies against lung-enriched targets and dnDSA conferred increased CLAD risk. The study is observational. Authors include Tereza Martinu and Stephen Juvet.

Details

doi
10.1016/j.healun.2025.02.1577
pmid
39971216
authors
Vosoughi D, Ulahannan A, Li Q, Huszti E, Chruscinski A, Birriel D, Madu G, Teskey G, Aversa M, Martinu T, Juvet S
journal
The Journal of Heart and Lung Transplantation
year
2025
volume
44
issue
7
pages
1109-1119

Sources and links

Related

Links from this record

Linked from (derived)

Known gaps in this record

  • full text not read (abstract only)
  • funding statement and grant numbers
  • full author affiliations (only the PubMed affiliation text was checked for named centres)

Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.